News
SLXNW
0.0632
-1.10%
-0.0007
Weekly Report: what happened at SLXNW last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at SLXNW last week (0224-0228)?
Weekly Report · 03/03 10:42
SILEXION THERAPEUTICS CORP: ANTICIPATES SHARING INITIAL RESULTS FROM SIL-204 STUDY IN MARCH 2025
Reuters · 02/25 13:30
Weekly Report: what happened at SLXNW last week (0217-0221)?
Weekly Report · 02/24 10:42
Weekly Report: what happened at SLXNW last week (0210-0214)?
Weekly Report · 02/17 10:40
Weekly Report: what happened at SLXNW last week (0203-0207)?
Weekly Report · 02/10 10:36
Weekly Report: what happened at SLXNW last week (0127-0131)?
Weekly Report · 02/03 10:39
BUZZ-U.S. STOCKS ON THE MOVE-89Bio, Brinker, Apple
Reuters · 01/29 15:47
SILEXION THERAPEUTICS REPORTS STRONG TUMOR GROWTH REDUCTION FROM SYSTEMIC ADMINISTRATION OF SIL-204 IN PRECLINICAL PANCREATIC CANCER MODELS
Reuters · 01/28 13:30
Weekly Report: what happened at SLXNW last week (0120-0124)?
Weekly Report · 01/27 10:41
Weekly Report: what happened at SLXNW last week (0113-0117)?
Weekly Report · 01/20 10:35
SILEXION THERAPEUTICS- PRICING OF PUBLIC OFFERING OF AGGREGATE 3.7 MLN ORDINARY SHARES AND WARRANTS AT COMBINED PRICE OF $1.35 PER SHARE AND WARRANT
Reuters · 01/16 01:00
SILEXION THERAPEUTICS ANNOUNCES PRICING OF $5.0 MILLION PUBLIC OFFERING
Reuters · 01/16 01:00
SILEXION THERAPEUTICS CORP - AMENDMENT INTRODUCES ACCELERATED PURCHASE MECHANISM UNTIL DECEMBER 31, 2025
Reuters · 01/15 21:03
SILEXION THERAPEUTICS ANNOUNCES ADDITIONAL PROMISING PRECLINICAL DATA FOR SIL-204, DEMONSTRATING IMPRESSIVE SYNERGY WITH FIRST-LINE PANCREATIC CANCER CHEMOTHERAPIES
Reuters · 01/15 21:01
SILEXION THERAPEUTICS CORP - TO INITIATE PRECLINICAL STUDIES FOR SIL-204 IN COLORECTAL CANCER
Reuters · 01/15 21:01
SILEXION THERAPEUTICS CORP FILES FOR OFFERING OF UP TO 2.6 MLN ORDINARY SHARES TOGETHER WITH ORDINARY WARRANTS - SEC FILING
Reuters · 01/14 11:22
Weekly Report: what happened at SLXNW last week (0106-0110)?
Weekly Report · 01/13 10:36
Weekly Report: what happened at SLXNW last week (1230-0103)?
Weekly Report · 01/06 10:42
Weekly Report: what happened at SLXNW last week (1223-1227)?
Weekly Report · 12/30/2024 10:37
More
Webull provides a variety of real-time SLXNW stock news. You can receive the latest news about Silexion Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About SLXNW
More
Silexion Therapeutics Corp is an oncology-focused biotechnology company. The Company is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.